Drug Profile
Tifenazoxide
Alternative Names: NN 414Latest Information Update: 02 Feb 2017
Price :
$50
*
At a glance
- Originator Novo Nordisk
- Class Antihyperglycaemics; Cyclic S oxides; Heterocyclic bicyclo compounds; Small molecules
- Mechanism of Action Potassium channel agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Type 2 diabetes mellitus
Most Recent Events
- 02 Feb 2017 Discontinued - Phase-II for Type-2 diabetes mellitus in Denmark (PO)
- 06 Nov 2003 Suspended - Phase-II for Type-2 diabetes mellitus in Denmark (PO)
- 16 Sep 2003 Data presented at the 18th International Diabetes Federation Congress (IDF-2003) have been added to the adverse events and Diabetes pharmacokinetics sections